Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy. I tried YSL’s latest formula with a large dash of skepticism. Why would this one ...

Stop sitting around wondering how you can alleviate your office aches and invest in some chair cushions that do the job. By Terri Williams Updated Jun 4, 2024 1:05 PM EDT Add Popular Science (opens in ...

In this post, we will show you how to create email templates in the new Outlook app for Windows 11. Creating email or message templates in Microsoft Outlook (classic) involved manually composing an ...

If Python developers have one consistent gripe about their beloved language, it tends to be this: Why is it so hard to take a Python program and deploy it as a standalone artifact, the way C, C++, ...

As the energy price shock threatens to spread through the economy, it’s a good time to search for assets that can provide inflation resilience in portfolios. Inflation had been on a declining slope ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...